12-25245350-C-G
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM1PM2PM5PP3_ModeratePP5_Very_Strong
The ENST00000311936.8(KRAS):c.35G>C(p.Gly12Ala) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000137 in 1,460,566 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G12D) has been classified as Likely pathogenic.
Frequency
Consequence
ENST00000311936.8 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
KRAS | NM_033360.4 | c.35G>C | p.Gly12Ala | missense_variant | 2/6 | ENST00000256078.10 | NP_203524.1 | |
KRAS | NM_004985.5 | c.35G>C | p.Gly12Ala | missense_variant | 2/5 | ENST00000311936.8 | NP_004976.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
KRAS | ENST00000256078.10 | c.35G>C | p.Gly12Ala | missense_variant | 2/6 | 1 | NM_033360.4 | ENSP00000256078 | A1 | |
KRAS | ENST00000311936.8 | c.35G>C | p.Gly12Ala | missense_variant | 2/5 | 1 | NM_004985.5 | ENSP00000308495 | P4 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome AF: 0.00000137 AC: 2AN: 1460566Hom.: 0 Cov.: 31 AF XY: 0.00000138 AC XY: 1AN XY: 726502
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Multiple myeloma Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | Xiao lab, Department of Pathology, Memorial Sloan Kettering Cancer Center | Aug 31, 2019 | - - |
KRAS-related disorder Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Oct 12, 2022 | The KRAS c.35G>C variant is predicted to result in the amino acid substitution p.Gly12Ala. To our knowledge, this variant has not been reported as a germline variant in individuals with Noonan/RASopathy phenotypes. However, several KRAS missense variants affecting Gly12, including p.Gly12Ala, have been reported as a somatic variant in multiple cancers (see for example - Brose et al. 2002. PubMed ID: 12460918; Lièvre et al. 2006. PubMed ID: 16618717). This variant has not been reported in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. This variant is interpreted as likely pathogenic. - |
Malignant tumor of urinary bladder;C0023467:Acute myeloid leukemia;C0024623:Gastric cancer;C0242379:Lung cancer;C0346153:Familial cancer of breast;C0917804:Cerebral arteriovenous malformation;C1838329:Toriello-Lacassie-Droste syndrome;C1860991:Noonan syndrome 3;C2674723:Autoimmune lymphoproliferative syndrome type 4;C2931038:Familial pancreatic carcinoma;C3809005:Cardiofaciocutaneous syndrome 2;C4552097:Linear nevus sebaceous syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Juno Genomics, Hangzhou Juno Genomics, Inc | - | PM2_Supporting+PM5_Strong+PP3_Moderate+PS4 - |
not provided Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | Department of Pathology and Laboratory Medicine, Sinai Health System | - | - - |
Non-small cell lung carcinoma Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Dec 07, 2007 | - - |
Lung cancer Pathogenic:1
Likely pathogenic, no assertion criteria provided | clinical testing | Key Laboratory of Carcinogenesis and Cancer Invasion, Central South University | - | - - |
Gallbladder cancer Pathogenic:1
Pathogenic, no assertion criteria provided | research | Institute of Medical Sciences, Banaras Hindu University | Oct 30, 2020 | - - |
Neoplasm Other:1
-, criteria provided, single submitter | clinical testing | Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital | Jul 31, 2024 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at